Evidence map›Paper›PMID 28358144›Full record

ArticleScientific reports2017

Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment.

Sergey O Bachurin, Elena F Shevtsova, Galina F Makhaeva, Vladimir V Grigoriev, Natalia P Boltneva, Nadezhda V Kovaleva, Sofya V Lushchekina, Pavel N Shevtsov, Margarita E Neganova, Olga M Redkozubova and 8 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The Dawn of Mitophagy: What Do We Know by Now?Current neuropharmacology · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Sergey O BachurinInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Elena F ShevtsovaInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Galina F MakhaevaInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Vladimir V GrigorievInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Natalia P BoltnevaInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Nadezhda V KovalevaInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Sofya V LushchekinaInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Pavel N ShevtsovInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Margarita E NeganovaInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Olga M RedkozubovaInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Elena V BovinaInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Alexey V GabrelyanInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Vladimir P FisenkoDepartment of Pharmacology, Therapeutic Faculty, I. M. Setchenov Moscow Medical Academy, ul. Bol'shaya Pirogovskaya 2/6, Moscow, 119881 Russia.
Vladimir B SokolovInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Alexey Yu AksinenkoInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Valentina EcheverriaUniversidad San Sebastián, General Cruz 1577, Concepción, Chile.
George E BarretoDepartamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia.
Gjumrakch AlievInstitute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Institute of Physiologically Active Compounds · RUInstitute of Biochemical Physics NM Emanuel · RUPontificia Universidad Javeriana · COSan Sebastián University · CLSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new group of compounds, promising for the design of original multitarget therapeutic agents for treating neurodegenerative diseases, based on conjugates of aminoadamantane and carbazole derivatives was synthesized and investigated. Compounds of these series were found to interact with a group of targets that play an important role in the development of this type of diseases. First of all, these compounds selectively inhibit butyrylcholinesterase, block NMDA receptors containing NR2B subunits while maintaining the properties of MK-801 binding site blockers, exert microtubules stabilizing properties, and possess the ability to protect nerve cells from death at the calcium overload conditions. The leading compound C-2h has been shown the most promising effects on all analyzed parameters. Thus, these compounds can be regarded as promising candidates for the design of multi-target disease-modifying drugs for treatment of AD and/or similar neuropathologies.

Indexed as

Alzheimer DiseaseAmantadineCarbazolesCarboxylesteraseCholinesterase InhibitorsDrug DesignErythrocytesHumansMemantineMicrotubulesMolecular Docking SimulationProtein BindingReceptors, N-Methyl-D-AspartateAmantadinecarbazoleCarbazolesCarboxylesteraseCholinesterase InhibitorsMemantineReceptors, N-Methyl-D-Aspartate

Identifiers

PMID28358144
PMCPMC5372361
OpenAlexW2603144737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.